---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021284"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:00:41.886735+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences reports Q1 2023 net loss of $17.5M; FDA backs Phase 3 trial design for choroidal melanoma

## Summary
- Cash and marketable securities $173.5M as of March 31, 2023; cash runway into 2025.
- Net loss $17.5M for Q1 2023 vs $12.8M in Q1 2022; R&D expense $14.4M (up from $8.3M).
- FDA Type C meeting supports global Phase 3 trial (≈100 patients, 2:1:2 randomized) for early-stage choroidal melanoma.
- Phase 2 enrollment complete; updated interim data expected 2H 2023; Phase 1 NMIBC data also due 2H 2023.
- Appointed Patrick Nealon as SVP, Clinical Development Operations to lead late-stage development.

## SEC filing metadata
- accession: 0000950170-23-021284
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000095017023021284/0000950170-23-021284-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000095017023021284/aura-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021284
- JSON: https://secwatch.observer/filing/0000950170-23-021284.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021284.txt

## Key facts
- Earnings Releases
  Aura Biosciences, Inc. reported the quarter ended March 31, 2023 results: net income $17.5 million.
  - Period: the quarter ended March 31, 2023
  - Net income: $17.5 million
  - Result: reported results
  source text: On May 11, 2023, Aura Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000095017023021284/0000950170-23-021284-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.